How is it different from alglucosidase alfa?

It is engineered with more mannose-6-phosphate to improve uptake into muscle cells. In the phase 3 COMET trial it improved respiratory function and met non-inferiority versus alglucosidase alfa.

It is administered by a healthcare professional as an intravenous infusion, typically every two weeks, with weight-based dosing. It is not an oral or self-administered product.

What are the main safety concerns?

Infusion-associated reactions are common, and serious hypersensitivity including anaphylaxis can occur. Most patients also develop anti-drug antibodies. Infusions are given in a setting equipped to manage reactions.

Does it treat the brain or nervous system?

No. It is an intravenous enzyme that acts on peripheral muscle and is not designed to correct central nervous system disease.

EMA-approvedaka Nexviazyme

Avalglucosidase alfa — Complete Research Guide (2026)

Last updated 2026-06-30

TL;DR

Avalglucosidase alfa (also known as Nexviazyme) is a peptide catalogued under Enzymes (Pompe (2nd gen)). Neutral reference entry; EU status: EU-approved prescription medicine.

What is Avalglucosidase alfa?

Avalglucosidase alfa (brand name Nexviazyme in the US, Nexviadyme in the EU) is a recombinant human acid alpha-glucosidase (GAA) engineered with roughly 15-fold more mannose-6-phosphate than earlier enzyme, improving uptake into muscle cells. It is an FDA-approved enzyme replacement therapy, granted approval in August 2021 for late-onset Pompe disease, and later approved in the EU and other regions.

It is a prescription-only, intravenously infused biologic; it is not a research chemical or a supplement.

The evidence base includes a pivotal head-to-head phase 3 randomized controlled trial (COMET) versus the older standard alglucosidase alfa, plus long-term extension and real-world data.

How does Avalglucosidase alfa work?

Pompe disease is caused by deficient lysosomal acid alpha-glucosidase, leading to glycogen accumulation in skeletal and respiratory muscle.

Avalglucosidase alfa supplies functional enzyme that is taken up via mannose-6-phosphate receptors into lysosomes, where it breaks down accumulated glycogen.

What does the research say about Avalglucosidase alfa?

In the pivotal phase 3 COMET trial, avalglucosidase alfa improved respiratory function (upright forced vital capacity) and was non-inferior to alglucosidase alfa in treatment-naive late-onset Pompe disease. ^[1]
Improvements in forced vital capacity and 6-minute walk distance were broadly maintained through 97 weeks of continued treatment in the COMET extension. ^[2]
A real-world case series reported stabilization or improvement in patients who switched from alglucosidase alfa to avalglucosidase alfa. ^[4]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial — Diaz-Manera J et al., Lancet Neurology 2021. (Phase 3 randomized controlled (equivalence) trial)
[2] Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks: A Phase 3 Randomized Clinical Trial — Kishnani PS et al., JAMA Neurology 2023. (Phase 3 randomized controlled trial (extension))
[3] Applying the win ratio method in clinical trials of orphan drugs: an analysis of data from the COMET trial of avalglucosidase alfa in patients with late-onset Pompe disease — Boentert M et al., Orphanet Journal of Rare Diseases 2024. (Secondary analysis of RCT data)
[4] Real-world outcomes from a series of patients with late onset Pompe disease who switched from alglucosidase alfa to avalglucosidase alfa — Carter C et al., Frontiers in Genetics 2024. (Real-world case series)
[5] Pompe disease: Unmet needs and emerging therapies — George KA et al., Molecular Genetics and Metabolism 2024. (Narrative review)
[6] Comprehensive review of recent advances in Pompe disease: pathogenesis, management, and future directions — Li G et al., Frontiers in Neurology 2026. (Review)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

In clinical use the drug is administered by a healthcare professional as an intravenous infusion, typically every two weeks, with the dose calculated by body weight.

This is context only and not a recommendation; the exact regimen, premedication, and monitoring are determined by the treating specialist per the approved label.

Side effects & safety profile

The most common adverse events are infusion-associated reactions (for example headache, fatigue, nausea, urticaria, flushing), which may require slowing or stopping the infusion and premedication.

Serious hypersensitivity, including anaphylaxis, has occurred, so infusions are given where reactions can be managed.

Anti-drug antibodies develop in most treated patients and can affect tolerability, though their long-term impact on efficacy is still being studied; as an intravenous enzyme, it targets peripheral muscle and does not correct any central nervous system pathology.

Stacking & combinations

This is a single-agent enzyme replacement therapy for a specific genetic disease and is not intended to be combined or stacked with other peptides or performance compounds.

Finding Avalglucosidase alfa vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

It is FDA-approved (August 2021) as an enzyme replacement therapy for late-onset Pompe disease, a rare inherited disorder caused by acid alpha-glucosidase deficiency. It is also approved in the EU and other regions.

References

[1] Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial — Diaz-Manera J et al., Lancet Neurology 2021. PMID: 34800399. View sourceStudy: Phase 3 randomized controlled (equivalence) trialAvalglucosidase alfa improved forced vital capacity and met the non-inferiority threshold versus alglucosidase alfa in late-onset Pompe disease.
[2] Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks: A Phase 3 Randomized Clinical Trial — Kishnani PS et al., JAMA Neurology 2023. PMID: 37036722. View sourceStudy: Phase 3 randomized controlled trial (extension)Respiratory and functional gains were generally sustained through 97 weeks of avalglucosidase alfa treatment.
[3] Applying the win ratio method in clinical trials of orphan drugs: an analysis of data from the COMET trial of avalglucosidase alfa in patients with late-onset Pompe disease — Boentert M et al., Orphanet Journal of Rare Diseases 2024. PMID: 38216959. View sourceStudy: Secondary analysis of RCT dataA win-ratio reanalysis of COMET favored avalglucosidase alfa over alglucosidase alfa across combined efficacy endpoints.
[4] Real-world outcomes from a series of patients with late onset Pompe disease who switched from alglucosidase alfa to avalglucosidase alfa — Carter C et al., Frontiers in Genetics 2024. PMID: 38313679. View sourceStudy: Real-world case seriesPatients switched from alglucosidase alfa to avalglucosidase alfa generally showed stabilization or improvement in clinical measures.
[5] Pompe disease: Unmet needs and emerging therapies — George KA et al., Molecular Genetics and Metabolism 2024. PMID: 39418752. View sourceStudy: Narrative reviewReviews current enzyme replacement therapies including avalglucosidase alfa and remaining unmet needs in Pompe disease.
[6] Comprehensive review of recent advances in Pompe disease: pathogenesis, management, and future directions — Li G et al., Frontiers in Neurology 2026. PMID: 41783848. View sourceStudy: ReviewSummarizes pathogenesis and current management of Pompe disease, positioning avalglucosidase alfa among approved enzyme therapies.

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.